Cardiac extracorporeal shock wave therapy (ESWT) provides symptom improvement for patients with end-stage coronary artery disease (EnD-CAD), but has reduced effects on angiogenesis and heart function recovery for those with concurrent EnD-CAD and end-stage renal disease (ESRD). A prospective study of ESWT in EnD-CAD patients found increased circulating endothelial progenitor cells and left ventricular ejection fraction at 6 months in the EnD-CAD group but not the higher-risk EnD-CAD/ESRD group. While ESWT was well-tolerated, the EnD-CAD/ESRD patients experienced more adverse clinical events before and after treatment. Thus, ESWT's long-
Cardiac extracorporeal shock wave therapy (ESWT) provides symptom improvement for patients with end-stage coronary artery disease (EnD-CAD), but has reduced effects on angiogenesis and heart function recovery for those with concurrent EnD-CAD and end-stage renal disease (ESRD). A prospective study of ESWT in EnD-CAD patients found increased circulating endothelial progenitor cells and left ventricular ejection fraction at 6 months in the EnD-CAD group but not the higher-risk EnD-CAD/ESRD group. While ESWT was well-tolerated, the EnD-CAD/ESRD patients experienced more adverse clinical events before and after treatment. Thus, ESWT's long-
Cardiac extracorporeal shock wave therapy (ESWT) provides symptom improvement for patients with end-stage coronary artery disease (EnD-CAD), but has reduced effects on angiogenesis and heart function recovery for those with concurrent EnD-CAD and end-stage renal disease (ESRD). A prospective study of ESWT in EnD-CAD patients found increased circulating endothelial progenitor cells and left ventricular ejection fraction at 6 months in the EnD-CAD group but not the higher-risk EnD-CAD/ESRD group. While ESWT was well-tolerated, the EnD-CAD/ESRD patients experienced more adverse clinical events before and after treatment. Thus, ESWT's long-
Cardiac extracorporeal shock wave therapy (ESWT) provides symptom improvement for patients with end-stage coronary artery disease (EnD-CAD), but has reduced effects on angiogenesis and heart function recovery for those with concurrent EnD-CAD and end-stage renal disease (ESRD). A prospective study of ESWT in EnD-CAD patients found increased circulating endothelial progenitor cells and left ventricular ejection fraction at 6 months in the EnD-CAD group but not the higher-risk EnD-CAD/ESRD group. While ESWT was well-tolerated, the EnD-CAD/ESRD patients experienced more adverse clinical events before and after treatment. Thus, ESWT's long-
Reduced effects of cardiac extracorporeal shock wave therapy on
angiogenesis and myocardial function recovery in patients with end stage coronary artery and renal diseases
Sung P, Fu M, Chiang H, Huang C, Chu C, Lee MS, Yip H.
Biomedical Journal 2020.
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death
worldwide with a growing incidence, according for more than 15 million global deaths annually. Of them, although diffuse coronary artery disease (CAD) occurred in less than 5% of ASCVD, it has significantly higher risk for heart failure or sudden cardiac death compared with single or multiple vessel CAD. Patients with ASCVD usually have multiple vascular involvement and comorbidities due to sharing common atherosclerotic risk factors and pathology of chronic systemic inflammation. Kidney involvement was usually observed in patients with diffuse CAD , especially for those with poorly controlled diabetes. Unfortunately, even with efforts in treating and preventing progression of chronic kidney disease (CKD), a part of patients with CAD and CKD eventually developed end-stage renal disease (ESRD). .This was a single-center prospective study to test the safety and efficacy of cardiac ESWT in the patients with concomitant EnD-CAD and ESRD.This journal was prospective study between August 2016 and January 2019. The result of this journal All participants tolerated cardiac ESWT without any relevant side effects such as skin allergic reaction, local redness/tenderness or cardiac arrhythmia. There were similar baseline comorbidities and clinical features between two groups, but the EnD-CAD/ESRD group had significantly higher serum potassium level as well as lower renal function and lipid profile (all p-values <0.03). After cardiac ESWT, the patients in both groups had significant improvement in angina and dyspnea at 1 year (all p-values <0.03). However, the EnD-CAD/ESRD group did not have increase in either circulating EPC levels or LVEF at 6 months (p 1.000). In contrast, the EnD-CAD group had gradually improving levels of circulating EPC surface markers and increased LV systolic function (p 0.092). Notably, patients in the EnD-CAD/ESRD group suffered from high incidental clinical adverse events before and after enrollment into the ESWT study (p 0.132). The conclusion of this journal is although cardiac ESWT provided mprovement of clinical symptoms in the EnD-CAD patients, its long-term effects on the angiogenesis and LVEF were reduced for those high-risk patients with concomitant EnD-CAD and ESRD. Journal Reading Will be presented by Anita Revera Sari On Monday, 26th May 2021